Research Article

Efficacy and Safety of Wenxin Granules and Propafenone in Treatment of Atrial Premature Beats: A Systematic Review and Meta-Analysis

Table 3

Characteristics of included RCTs on Wenxin granules and propafenone for treating atrial premature beats.

Study IDSample sizeSex (M/F)APB duration (units: year)Age (years, average or range)InterventionsOutcomes
TCCourse of the treatment

Shao MF 2012 [12]T:32 C:30T:15/17 C:14/16T:0.03–12 (mean: 2.6) C:0.03–11.5 (mean: 2.4)T:20–78 (Mean: 56) C:22–76 (Mean: 53)Propafenone 150 mg Tid po and Wenxin granules 5 g Tid poPropafenone 150 mg Tid po4 weeks①②
Fan YN 2018 [13]T:30 C:32T:19/11 C:20/12NRT:68.23 ± 12.29 C:66.18 ± 10.63Propafenone 100 mg Tid po and Wenxin granules 5 g Tid poPropafenone 100 mg Tid po4 weeks①②
Wang HP 2012 [5]T:60 C:6062/581–975.34 ± 4.32Propafenone 100 mg Tid po and Wenxin granules 9 g Tid poPropafenone 100 mg Tid po4 weeks①②
Zhao S 2013 [4]T:70 C:7071/69NR75.33 ± 4.31Propafenone 100 mg Tid po and Wenxin granules 1 package Tid poPropafenone 100 mg Tid po4 weeks①②
Wang XS 2013 [14]T:42 C:42T:23/19 C:22/200.25–10T:48.12 ± 3.89 C:47.69 ± 3.54Propafenone 150 mg Tid po and Wenxin granules 5 g Tid poPropafenone 150 mg Tid po4 weeks①②
Du WF 2008 [15]T:30 C:3034/26NR>60 (Mean:73.5)Wenxin granules 1 package Tid poPropafenone 150 mg Tid po4 weeks①②
Li ZM 2010 [16]T:77 C:51T:48/29 C:32/19NRT:56.32 ± 19.65 C:55.19 ± 17.28Wenxin granules 9 g Tid poPropafenone 150 mg Tid po4 weeks①②
Meng FH 2013 [17]T:59 C:59T:36/23 C:35/24NRT:41–77 (Mean: 57) C:40–77 (Mean: 57)Wenxin granules 9 g Tid poPropafenone 150 mg Tid po4 weeks①②
Li L 2009 [18]T:96 C:84T:51/45 C:44/40NRT:Mean:63.2 C:Mean:60.9Wenxin granules 9 g 2–3 times a day poPropafenone 100–150 mg 2–3 times a day po15–30 days
Cui SZ 2008 [19]T:60 C:30NRNRT:72.80 ± 12.40 C:70.60 ± 14.40Wenxin granules 9 g Tid poPropafenone 100 mg Tid po4 weeks①②
Liu JF 2009 [20]T:75 C:75T:40/35 C:36/39NRT:56.20 ± 5.40 C:54.60 ± 4.90Wenxin granules 9 g Tid poPropafenone 100 mg Tid po4 weeks

Outcome: ①Clinical efficiency; ②Drug adverse reactions. #T: treatment group; C: control group; M: males; F: females; NR: not reported; APBs: atrial premature beats.